Does Rallies show 13F holders for ARGX?

Yes. Rallies tracks hedge fund and 13F ownership data for ARGX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ARGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARGX. It does not provide personalized investment advice.

ARGX (Argenx) Stock Analysis - Hedge Fund Holdings

Argenx (ARGX) is a publicly traded Healthcare sector company. As of May 20, 2026, ARGX trades at $804.59 with a market cap of $48.27B and a P/E ratio of 0.00. ARGX moved +0.83% today. Year to date, ARGX is +0.42%; over the trailing twelve months it is +39.07%. Its 52-week range spans $510.06 to $934.62. Analyst consensus is strong buy with an average price target of $1,017.32. Rallies surfaces ARGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ARGX stock?

Hedge funds tracked by Rallies that own ARGX include Orbimed Advisors, Pinebridge Investments, Soros Fund, Centerbook Partners, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Argenx.

ARGX Key Metrics

Key financial metrics for ARGX
Metric	Value
Price	$804.59
Market Cap	$48.27B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$934.62
52-Week Low	$510.06
Volume	276.25K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding ARGX

Orbimed Advisors holds 136.90K shares of ARGX, changed -6.23% as of Mar 31, 2026.
Pinebridge Investments holds 95.72K shares of ARGX, changed +24.74% as of Sep 30, 2025.
Soros Fund holds 30.00K shares of ARGX, changed +0.00% as of Mar 31, 2024.
Centerbook Partners holds 13.93K shares of ARGX, changed +393.59% as of Mar 31, 2026.
Eisler Capital holds 7.61K shares of ARGX, changed +0.00% as of Jun 30, 2024.

Latest ARGX News

argenx wins FDA label expansion for VYVGART and Hytrulo across four gMG serotypes — May 8, 2026
argenx drops after May 7 Q1 results update; May 10 VYVGART FDA decision ahead — May 7, 2026
argenx Posts 63% Q1 Sales Rise to $1.3B, Sees PDUFA May 10 — May 7, 2026
argenx Elevates COO Karen Massey to CEO, Authorizes 10% Share Issuance — May 6, 2026
argenx jumps as investors eye May 10 FDA decision for VYVGART seronegative gMG — May 4, 2026

ARGX Analyst Consensus

20 analysts cover ARGX: 0 strong buy, 18 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $1,017.32.

Common questions about ARGX

Who owns ARGX stock?: Hedge funds tracked by Rallies that own ARGX include Orbimed Advisors, Pinebridge Investments, Soros Fund, Centerbook Partners, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Argenx.
Does Rallies show 13F holders for ARGX?: Yes. Rallies tracks hedge fund and 13F ownership data for ARGX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ARGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARGX. It does not provide personalized investment advice.